Gamelin Erick 4

What Happened Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), received a grant of 38,584 restricted stock units (RSUs) on May 18, 2026. The grant is reported at $0.00 per share (typical for RSU awards, which are compensation rather than a market purchase). These RSUs represent contingent rights to receive one share of Acrivon's common stock upon vesting.

Key Details

• Transaction type and date: Grant (Code A) on 2026-05-18; reported on Form 4 filed 2026-05-20.
• Shares/price: 38,584 RSUs granted at $0.00 (acquisition value $0).
• Vesting: 16.67% of the RSUs vest on November 18, 2026; the remainder vests in 10 substantially equal quarterly installments thereafter, subject to continuous service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing was submitted two days after the grant (not indicated as late).

Context RSUs are compensation awards that convert to actual shares only as they vest; they are not an open‑market purchase or sale. Because this is a grant for service/retention, it does not by itself indicate the insider bought or sold stock in the open market.